Anavex Life Sciences Corp. Stock Insider Trading
Based on the 100 latest insides trades, we have calculated the insider power to be positive at a ratio of 39.822.
In total, the insiders bought 6 930 241 and sold 718 436 AVXL shares in the last 100 trades.
| Date | Action | Amount | Person | Type |
| Jun 27, 2022 | Buy | 50 000 | Velden Claus Vander | Stock Option (Right to Buy) |
| Jun 27, 2022 | Buy | 50 000 | Thomas Steffen | Stock Option (Right to Buy) |
| Jun 27, 2022 | Buy | 50 000 | Donhauser Peter D.o. | Stock Option (Right to Buy) |
| Jun 27, 2022 | Buy | 50 000 | Skarpelos Athanasios | Stock Option (Right to Buy) |
| Jun 27, 2022 | Buy | 50 000 | Ma Jiong | Stock Option (Right to Buy) |
| May 25, 2022 | Buy | 50 000 | Skarpelos Athanasios | Stock Option (Right to Buy) |
| May 25, 2022 | Sell | 50 000 | Skarpelos Athanasios | Common Stock |
| May 25, 2022 | Buy | 50 000 | Skarpelos Athanasios | Common Stock |
| Aug 02, 2021 | Buy | 25 000 | Ma Jiong | Stock Option (Right to Buy) |
| Aug 02, 2021 | Buy | 40 000 | Boenisch Sandra | Stock Option (Right to Buy) |
| Aug 02, 2021 | Buy | 25 000 | Velden Claus Vander | Stock Option (Right to Buy) |
| Aug 02, 2021 | Buy | 25 000 | Skarpelos Athanasios | Stock Option (Right to Buy) |
| Aug 02, 2021 | Buy | 25 000 | Donhauser Peter D.o. | Stock Option (Right to Buy) |
| Aug 02, 2021 | Buy | 500 000 | Missling Christopher U | Stock Option (Right to Buy) |
| Aug 02, 2021 | Buy | 25 000 | Thomas Steffen | Stock Option (Right to Buy) |
| Jun 29, 2021 | Sell | 51 620 | Missling Christopher U | Common Stock |
| Jun 29, 2021 | Buy | 51 620 | Missling Christopher U | Common Stock |
| Jun 29, 2021 | Sell | 51 620 | Missling Christopher U | Stock Option (Right to Buy) |
| Jun 29, 2021 | Buy | 25 000 | Boenisch Sandra | Common Stock |
| Jun 29, 2021 | Sell | 166 696 | Boenisch Sandra | Common Stock |
| Jun 29, 2021 | Sell | 25 000 | Boenisch Sandra | Stock Option (Right to Buy) |
| Jun 29, 2021 | Buy | 35 000 | Boenisch Sandra | Common Stock |
| Jun 29, 2021 | Buy | 106 696 | Boenisch Sandra | Common Stock |
| May 21, 2021 | Sell | 37 500 | Favus Elliot | Stock Option (Right to Buy) |
| May 21, 2021 | Buy | 1 500 | Favus Elliot | Common Stock |
| May 21, 2021 | Buy | 37 500 | Favus Elliot | Common Stock |
| May 21, 2021 | Buy | 1 500 | Favus Elliot | Common Stock |
| May 21, 2021 | Buy | 50 000 | Favus Elliot | Common Stock |
| May 21, 2021 | Buy | 1 500 | Favus Elliot | Common Stock |
| May 21, 2021 | Buy | 1 500 | Favus Elliot | Common Stock |
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinica... AVXL Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
